Cargando…
Defeat mutant KRAS with synthetic lethality
Ras proteins are considered as the founding members of a large superfamily of small GTPases that control fundamental cellular functions. Mutationally activated RAS genes were discovered in human cancer cells more than 3 decades ago, but intensive efforts on Ras structure, biochemistry, function and...
Autores principales: | Pang, Xiufeng, Liu, Mingyao |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Taylor & Francis
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5680709/ https://www.ncbi.nlm.nih.gov/pubmed/27463838 http://dx.doi.org/10.1080/21541248.2016.1213783 |
Ejemplares similares
-
A combination therapy for KRAS-mutant lung cancer by targeting synthetic lethal partners of mutant KRAS
por: Pang, Xiufeng, et al.
Publicado: (2016) -
CDK1 Is a Synthetic Lethal Target for KRAS Mutant Tumours
por: Costa-Cabral, Sara, et al.
Publicado: (2016) -
Suppression of KRas-mutant cancer through the combined inhibition of KRAS with PLK1 and ROCK
por: Wang, Jieqiong, et al.
Publicado: (2016) -
Correction: CDK1 Is a Synthetic Lethal Target for KRAS Mutant Tumours
por: Costa-Cabral, Sara, et al.
Publicado: (2016) -
Correction: CDK1 Is a Synthetic Lethal Target for KRAS Mutant Tumours
por: Costa-Cabral, Sara, et al.
Publicado: (2017)